Recently, FDA granted priority review of melflufen in combination with DEX for patients with MM whose disease were refractory to at least one PI, one immunomodulatory agent (IMiD), and one anti-CD38 mAb. This evidence concerns the gene CD38 and Miyoshi myopathy.